Hussain Kagzi

My first question is on our product pipeline. So , as I see there's a great jump in the Phase II molecule pipeline this year. So, if you could share some color on that. And additionally now if I zoom out and look at our pipeline data since FY18, so the total number of projects or molecules have not grown much from FY20 to FY24 like the total number was 76 in FY20 and now it's 88 So compared to the rise that we saw…

That's very helpful. And just in continuation to this. It's interesting that you mentioned that about biotech funding and all. So, you have said that FY25 will be a year in terms of normalized revenue, but if I see our exceptional performance in FY23 as we ll as FY24, this was in light of severe biotech funding pressure which of course forms a major part of our client cohort.

Got it. Thank you. That’s very helpful and wish you the best.